In the first half of 2009, the mainspring of Chong Kun Dang‘s sales growth turned out the drugs for the diseases of the circulatory system(hypertension, hyperlipidemia and thrombosis etc.).

Its leading item, 'Dilatrend(anti-hypertension drug)' showed good performance as usual and its Cozaar generic, ‘Salotan’ marked first place in the anti-hypertension drug market.

According to the Health Korea News' analysis based on the stock companies' data, in Chong Kun Dang's itemized sales for the first half of 2009, 6 items among its top 12 ETC drugs were the drugs for the diseases of the circulatory system. And among its top 5 ETC drugs, 4 items were the drugs for the diseases of the circulatory system.

The first placed item was 'Dilatrend' (25.5 billion won), followed by 'Salotan' (12.5 "), 'Anydipine'(5.8 ": anti-hypertehsion drug) and 'Lipilou' (4.5 ": anti-hyperlipidemia drug).

Especially, Chong Kung Dang ranked first place in the Cozaar generic market with its 'Salotan', outdistancing all its competitors such as Hanmi Pharmaceutical Co., Yuhan Corporation and Dong-A Pharmaceutical Co..

Its 'Simvalord' (32 billion won : anti-hyperlipidemia drug) and 'Pregrel' (21" : anti-thrombosis drug), ranked 10th and 12th respectively, are also the drugs for the diseases of the circulatory system.

Chong Kun Dang has shown more than 30% growth in out of hospital priscription amount in the first half of the 2009. And it is only Chong Kun Dang(30.18%) and Dong-A(34.57%) that marked more than 30% growth.<헬스코리아뉴스>

▶ 종근당, 순환기계 약물 위력 과시

Healthkoreanews 다른기사 보기